Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
Choice and switch of biologic drugs in juvenile idiopathic arthritis
CONCLUSION: In this study, we revealed the biologic drug usage and switch strategies in our JIA patients. Good responses were obtained in most of our patients with a reliable profile. However, studies on larger patient groups are needed to clarify these results.PMID:38204313 | DOI:10.24953/turkjped.2023.22 (Source: The Turkish Journal of Pediatrics)
Source: The Turkish Journal of Pediatrics - January 11, 2024 Category: Pediatrics Authors: Seher Şener Özge Başaran Ezgi Deniz Batu M üşerref Kasap Cüceoğlu Zeynep Bal ık Emil Aliyev Ya ğmur Bayındır Yelda Bilginer Seza Özen Source Type: research
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
Advanced targeted therapies including tumour necrosis factor inhibitors (TNFis) have transformed the clinical management of rheumatoid arthritis (RA). However, monoclonal antibody (MAb)-derived TNFis are associated with development of immunogenicity resulting in low circulating drug levels ().1 A genetic predictor of immunogenicity would have clinical utility by providing a pretreatment biomarker that could be used to inform therapy selection. Previous genetic studies of TNFi immunogenicity have focused on alleles within the HLA locus on chromosome 6.2–4 Patients were followed for 12 months with serum samples collect...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Yap, C. F., Nair, N., de Vries, A., Loeff, F. C., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A., Plant, D. Tags: Open access, ARD Letter Source Type: research
Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn ’s Disease: Secondary Analysis of the PYRAMID Registry
Traditional risk factors for serious infections with advanced therapies in patients with Crohn ’s disease (CD) have been assessed at baseline prior to starting therapy. We evaluated the impact of treatment response on the risk of serious infections in adalimumab-treated patients with CD through secondary analysis of the PYRAMID registry (NCT00524537). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - January 10, 2024 Category: Gastroenterology Authors: Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid S. Boland, John Chang, Christopher Ma, Vipul Jairath, Ronghui Xu, Siddharth Singh Source Type: research
Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis
CONCLUSION: Switching from adalimumab originator to SB5 for NIU does not result in clinically significant differences in treatment efficacy and safety.PMID:38194436 | DOI:10.1080/09273948.2023.2295544 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - January 9, 2024 Category: Allergy & Immunology Authors: Seok Hyeon Song Se Joon Woo Source Type: research
Better efficacy and lower recurrence rate with guselkumab treatment for generalized pustular psoriasis: A prospective cohort study from China
Clin Immunol. 2024 Jan 5:109899. doi: 10.1016/j.clim.2024.109899. Online ahead of print.ABSTRACTGeneralized pustular psoriasis (GPP) is a severe and uncommon form of psoriasis, for which treatment options are limited. There is an urgent need to expand the treatment options for GPP. Currently, adalimumab, secukinumab, and guselkumab are considered effective for GPP, but there is a lack of prospective direct comparative studies on their efficacy for GPP. We conducted a prospective, single-center, observational study on 50 GPP patients to compare the efficacy, safety, and recurrence rates of these three biologics. Adalimumab,...
Source: Clinical Immunology - January 7, 2024 Category: Allergy & Immunology Authors: Jiajing Lu Dawei Huang Nan Yang Hui Qin Yingyuan Yu Xiaoyuan Zhong Luyang Kong Yuxiong Jiang Jing Zhou Yuling Shi Source Type: research
Better efficacy, lower recurrence rate and decreased CD8 < sup > + < /sup > T < sub > RM < /sub > with guselkumab treatment for generalized pustular psoriasis: A prospective cohort study from China
Clin Immunol. 2024 Feb;259:109899. doi: 10.1016/j.clim.2024.109899. Epub 2024 Jan 5.ABSTRACTGeneralized pustular psoriasis (GPP) is a severe and uncommon form of psoriasis, for which treatment options are limited. There is an urgent need to expand the treatment options for GPP. Currently, adalimumab, secukinumab, and guselkumab are considered effective for GPP, but there is a lack of prospective direct comparative studies on their efficacy for GPP. We conducted a prospective, single-center, observational study on 50 GPP patients to compare the efficacy, safety, and recurrence rates of these three biologics. Adalimumab, sec...
Source: Clinical Immunology - January 7, 2024 Category: Allergy & Immunology Authors: Jiajing Lu Dawei Huang Nan Yang Hui Qin Yingyuan Yu Xiaoyuan Zhong Luyang Kong Yuxiong Jiang Jing Zhou Yuling Shi Source Type: research
Development of an in-line Raman analytical method for commercial-scale CHO cell culture process monitoring: Influence of measurement channels and batch number on model performance
In this study, an in-line Raman analytical method was developed for monitoring glucose, lactate, and viable cell density (VCD) in the Chinese hamster ovary (CHO) cell culture process during commercial production of biosimilar adalimumab (1500 L). The influence of different Raman measurement channels was considered to determine whether to merge data from different channels for model development. Raman calibration models were developed and optimized, with minimum root mean square error of prediction of 0.22 g L-1 for glucose in the range of 1.66-3.53 g L-1 , 0.08 g L-1 for lactate in the range of 0.15-1.19 g L-1 , 0.31 E6 ce...
Source: Biotechnology Journal - January 5, 2024 Category: Biotechnology Authors: Xu Yan Xiaoxiao Dong Yuxiang Wan Dong Gao Zhenhua Chen Ying Zhang Zhilong Zheng Kaifeng Chen Jingyu Jiao Yan Sun Zhuohong He Lei Nie Xiaohui Fan Haibin Wang Haibin Qu Source Type: research
Bibliometric analysis and visualisation of research hotspots and frontiers in Takayasu's arteritis
CONCLUSIONS: Although the area of TAK research is growing rapidly, intensive institutional and author collaboration has to be fostered in the future to fuel TAK research and information dissemination. Future research on TAK may revolve around cytokines, disease activity evaluation and clinical trials.PMID:38179700 | DOI:10.55563/clinexprheumatol/akl7x6 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - January 5, 2024 Category: Rheumatology Authors: Xiufang Kong Xiao Huang Wei Wang Source Type: research
